newsfilter
← Latest News
GlobeNewswire·

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) Progressed